Patents by Inventor Kumar N. Alagramam

Kumar N. Alagramam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240190929
    Abstract: An isolated polynucleotide includes a nucleic acid sequence that includes a cDNA coding sequence of a clarin-1 gene and a 3?UTR nucleic acid that is derived from the 3?UTR of the clarin-1 gene. The 3?UTR nucleic acid can enhance expression of clarin-1 in a cell transfected with the polynucleotide compared to a cell transfected with a similar polynucleotide devoid of the 3?UTR nucleic acid.
    Type: Application
    Filed: November 22, 2023
    Publication date: June 13, 2024
    Inventor: Kumar N. Alagramam
  • Patent number: 11827680
    Abstract: An isolated polynucleotide includes a nucleic acid sequence that includes a cDNA coding sequence of a clarin-1 gene and a 3?UTR nucleic acid that is derived from the 3?UTR of the clarin-1 gene. The 3?UTR nucleic acid can enhance expression of clarin-1 in a cell transfected with the polynucleotide compared to a cell transfected with a similar polynucleotide devoid of the 3?UTR nucleic acid.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: November 28, 2023
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventor: Kumar N. Alagramam
  • Patent number: 10561636
    Abstract: A method of treating a glycosylation-defective protein associated disease or disorder in a subject, the method includes administering to the subject a therapeutically effective amount of a Sarco/ER ATPase (SERCA) inhibitor.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: February 18, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Kumar N. Alagramam, Suhasini Gopal
  • Publication number: 20190231741
    Abstract: A method of treating a glycosylation-defective protein associated disease or disorder in a subject, the method includes administering to the subject a therapeutically effective amount of a Sarco/ER ATPase (SERCA) inhibitor.
    Type: Application
    Filed: October 10, 2017
    Publication date: August 1, 2019
    Inventors: Kumar N. Alagramam, Suhasini Gopal
  • Publication number: 20180282382
    Abstract: An isolated polynucleotide includes a nucleic acid sequence that includes a cDNA coding sequence of a clarin-1 gene and a 3?UTR nucleic acid that is derived from the 3?UTR of the clarin-1 gene. The 3?UTR nucleic acid can enhance expression of clarin-1 in a cell transfected with the polynucleotide compared to a cell transfected with a similar polynucleotide devoid of the 3?UTR nucleic acid.
    Type: Application
    Filed: November 6, 2015
    Publication date: October 4, 2018
    Inventor: Kumar N. Alagramam